Article
Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study

https://doi.org/10.1016/S1472-6483(10)60168-XGet rights and content

Abstract

This study was designed to determine if the efficiency of in-vitro maturation (IVM) in women with normal ovaries can be improved by gonadotrophin administration. 400 women were randomly allocated in four groups: group A, non-primed cycles; group B, human chorionic gonadotrophin (HCG)-primed cycles; group C, FSH-primed cycles; and group D, FSH- plus HCG-primed cycles. There were significant differences in the IVM rate among the groups. In groups where HCG was used, the overall maturation rate was higher (57.9% in group B and 77.4% in group D; 48.4% in group A and 50.8% in group C) and the percentage of total available metaphase II-stage oocytes was higher (60.4% in group B and 82.1% in group D; 48.4% in group A and 50.8% in group C). The overall clinical pregnancy rate per transfer (CPR) was 18.3% and the implantation rate (IR) was 10.6%. There was a difference in CPR among the groups: group D (29.9%) versus group A (15.3%), P = 0.023; group D versus group B (7.6%), P < 0.0001; group D versus group C (17.3%), P = 0.046. The results of this study are clearly in favour of FSH plus HCG priming. FSH priming and HCG priming alone showed no significant effects on clinical outcome.

Section snippets

Dr Fadini obtained his speciality in Gynaecology and Obstetrics and in Human Reproduction from the University of Milan, Italy. From 1985 to 1999 he directed the Unit of Reproductive Medicine and Endocrinology at San Gerardo University Hospital in Monza, University of Milan. He is Assistant Professor in the School of Specialization in Gynaecology and Obstetrics and at the School of Medical Biotechnologies, Faculty of Medicine, University of Milan-Bicocca. He has been Director of the Unit of

References (44)

  • RG Edwards

    Maturation in-vitro of human ovarian oocytes

    Lancet

    (1965)
  • A Gougeon et al.

    Influence of human menopausal gonadotropin on the recruitment of human ovarian follicles

    Fertility and Sterility

    (1990)
  • B Gulekli et al.

    Randomized, controlled trial of priming with 10,000 IU versus 20,000 IU of human chorionic gonadotropin in women with polycystic ovary syndrome who are undergoing in-vitro maturation

    Fertility and Sterility

    (2004)
  • ZX Jin et al.

    What is the smallest size of follicle to respond to human chorionic gonadotropin injection?

    Fertility and Sterility

    (2005)
  • AL Mikkelsen

    Strategies in human in-vitro maturation and their clinical outcome

    Reproductive BioMedicine Online

    (2005)
  • JB Russell et al.

    Unstimulated immature oocyte retrieval: early versus midfollicular endometrial priming

    Fertility and Sterility

    (1997)
  • J Smitz et al.

    Principal findings from a multicenter trial investigating the safety of follicular-fluid meiosis-activating sterol for in-vitro maturation of human cumulus-enclosed oocytes

    Fertility and Sterility

    (2007)
  • WY Son et al.

    Effect of gonadotrophin priming on in-vitro maturation of oocytes collected from women at risk of OHSS

    Reproductive BioMedicine Online

    (2006)
  • AM Suikkari et al.

    In-vitro maturation of eggs: is it really useful?

    Best Practice and Research. Clinical Obstetrics and Gynaecology

    (2007)
  • DG Altman et al.

    The revised CONSORT statement for reporting randomized trials: explanation and elaboration

    Annals of Internal Medicine

    (2001)
  • WM Buckett et al.

    Human chorionic gonadotropin for in-vitro oocyte maturation: does it improve the endometrium or implantation?

    The Journal of Reproductive Medicine

    (2004)
  • Cesana BM, Marubini E 1986 Dimensione del campione nella ricerca biomedica. Centro Zambon – Facoltà di Medicina e...
  • Cited by (0)

    Dr Fadini obtained his speciality in Gynaecology and Obstetrics and in Human Reproduction from the University of Milan, Italy. From 1985 to 1999 he directed the Unit of Reproductive Medicine and Endocrinology at San Gerardo University Hospital in Monza, University of Milan. He is Assistant Professor in the School of Specialization in Gynaecology and Obstetrics and at the School of Medical Biotechnologies, Faculty of Medicine, University of Milan-Bicocca. He has been Director of the Unit of Gynaecology and Obstetrics and Chief of the BIOGENESI Reproductive Medicine Centre at the Istituti Clinici Zucchi, in Monza since 2000.

    Declaration: The authors report no financial or commercial conflicts of interest.

    View full text